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ABSTRACT  
Objective: To assess the factors associated with anemia in renal transplant recipients with functioning 
grafts in Sana’a city, Yemen.  
Methods: One hundred and thirteen adult renal transplant recipients with functioning grafts were 
enrolled in this study in the period from Janury to December 2014. Biodata and clinical data were collected 
using a pre-designeddata collection sheet. Hemoglobin (Hb) concentration was measured, and anemia was 
defined as Hb concentration less than13.0 g/dLin males and less than 12.0 g/dL in females. The factors 
associated with anemia were analyzed, and independent predictors of post-transplant anemia (PTA) 
among renal transplant recipients were identified using a multivariable logistic regression model. 
Results: PTA was detected in 23.0% of renal transplant recipients with functioning grafts. Bivariate 
analysis showed a significant association of PTA with age of 50 years or older (Odds ratio (OR) = 2.7; 95% 
CI: 1.10–6.72; P = 0.03), history of acute rejection (OR = 3.6; 95% CI: 1.17–11.28; P = 0.019) and delayed 
graft function (OR = 6.2; 95% CI:1.60–24.16; P = 0.004). Multivariable analysis using a logistic regression 
model identified history of acute rejection (adjusted OR = 3.9; 95% CI: 1.11–12.94; P = 0.034) and delayed 
graft function (adjusted OR = 4.6; 95% CI: 1.07–19.81; P = 0.04) as independent risk factors for PTA among 
recipients. However, no association was found between PTA and recipient’s gender, graft source, 
immunosuppressive protocols, erythropoietin treatment or use of antihypertensive drugs.  
Conclusions: The prevalence of PTA among Yemeni renal transplant recipients is high, with history of 
acute rejection and delayed graft function being the independent risk factors. Therefore, it is 
recommended that physicians involved in renal transplantation consider the investigation and follow-up 
of transplant recipients for PTA and adopt appropriate preventive and therapeutic measures.  
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1. Introduction 
Anemia is an important risk factor for 
cardiovascular diseases and is related to left 
ventricular hypertrophy in renal transplant 
recipients. Moreover, severe anemia is shown to 
be strongly associated with reduced patient and 
graft survival (1–3). Therefore, early treatment 
of post-transplant anemia (PTA) may improve 
clinical outcomes in renal transplant recipients. 
Chronic anemia is commonly observed in 
patients with kidney dysfunction. The primary 
cause of anemia in this situation is the reduced 
production of erythropoietin (EPO) hormone by 
the kidneys. Renal transplantation is the 
treatment of choice for patients with end-stage 
kidney disease. Following successful renal 
transplantation, PTA is corrected via endogenous 
production of EPO by the renal transplant. 
However, such renal transplants may not 
function optimally in the majority of renal 
transplant recipients, leading to a high rate of 
PTA (4, 5). 
PTA prevalence rates were reported to range 
from 20.0% to 60.0%, depending on the criteria 
used for defining anemia (6–13). For instance, 
PTA was reported to be prevalent among 39.5% 
of Sudanese renal transplant recipients (14). In 
Egypt, 74.0% and 45.0% of renal transplant 
recipients were reported to show PTA within 
three and six months after renal transplantation, 
respectively (15). In addition, PTA prevalence 
rates ranging between 20.0% and 49.3% have 
been reported from several countries in Asia, 
Europe and the Americas (4, 6–13).  
Etiology of PTA is multi-factorial, where 
reported causes include blood loss either 
secondary to the transplantation surgery or 
during outpatient follow up for monitoring the 
renal allograft, insufficient diet that results in 
iron, vitamin B12 and folate deficiencies, 
infectious agents (e.g. cytomegalovirus or 
parvovirus B19 infection), donor age, 
different immunosuppressive regimens, acute 
rejection episodes, the degree of renal function 
and use of angiotensin-converting enzyme 
inhibitors (ACEIs) or angiotensin receptor 
blockers (ARBs) (6, 8, 11, 16–19). 
To the best of our knowledge, no published 
data are available on the prevalence and risk 
factors for PTA among Yemeni renal transplant 
recipients, which are necessary for the 
management of post-transplant complications. 
Therefore, the present study aimed to assess the 
prevalence and risk factors associated with PTA 
among renal transplant recipients with 
functioning grafts. 
2. Methods 
2.1. Study design, setting and subjects 
This cross-sectional study was conducted in Al-
Thawra Modern General Hospital (AMGH) in 
Sana'a city in the period from Janury to 
December 2014. One hundred and thirteen renal 
transplant recipients who had undergone renal 
transplantation at the Kidney Center of the 
hospital were recruited. All recipients had 
transplantation surgery before four months or 
longer and were subjected to 
immunosuppressive treatment to prevent graft 
rejection. Serum creatinine levels of all included 
recipients were less than 2 mg/dL, indicating 
functioning grafts. Patients who underwent a 
second renal transplantation, pregnant women, 
recipients aged less than 18 years were excluded 
from the study.  
2.2. Data and sample collection 
Five milliliters of venous blood were collected 
from each participant. In addition, data about 
recipient’s gender and age, donor-recipient 
relationship, immunosuppressive regimens, use 
of ACEIs and ARBs, EPO treatment prior to renal 
transplantation, graft function and history of 
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acute rejection episodes were collected using a 
pre-designed data collection sheet. 
2.3. Hemoglobin measurement  
Hb was measured using an automated ADVIA® 
2120i Hematology System (Siemens Healthcare 
Diagnostics, Dublin, Ireland). Anemia was 
defined as Hb concentrations less than 13.0 g/dL 
in males and less than 12.0 g/dL in females as 
established by the World Health Organization 
and adopted by the American Society of 
Transplantation (20). 
2.4. Statistical analysis 
Statistical analyses of data were performed using 
the Statistical Packages for Social Sciences (SPSS) 
software, version 13.0 (SPSS Inc., Chicago, IL, 
USA). Categorical variables were presented as 
frequencies and proportions. Differences or 
associations between variables were tested using 
Pearson’s chi-square test, which were considered 
statistically significant at P values <0.05. A 
bivariate logistic regression model was 
developed to identify the possible risk factors 
associated with PTA, and odds ratios (ORs) with 
their corresponding 95% confidence intervals 
(CIs) were reported. To identify the independent 
predictors of PTA, a multivariable logistic 
regression model was developed for variables 
with P values <0.07, and adjusted ORs with their 
95% CIs were reported.  
3. Results 
3.1. Characteristics of renal transplant 
recipients  
Table (1) shows the characteristics and PTA 
prevalence rates among renal transplant 
recipients in AMGH in Sana’a. The majority of 
recipients were males (63.7%; 72/113), aged 
less than 50 years (70.8%; 80/113), had a late 
PTA (71.7%; 81/113) and receiving renal 
transplants from a living related donor (77.9%; 
88/113). On the other hand, 59.3% (67/113) of 
renal transplant patients received a triple 
therapy of cyclosporine A (CsA), mycophenolate 
mofetil (MMF) and prednisone, while 
40.7%(46/113) received tacrolimus (Tac), MMF 
and prednisone. In addition, the majority of 
recipients had no history of acute graft rejection 
(86.7%; 98/113), receivedtreatment with 
ACEIs/ARBs (62.0%; 70/113), but did not 
receive EPO treatment (65.5%; 75/113). 
Regarding the graft function, immediate and 
delayed functions were observed in 91.2% and 
8.8% of renal transplant recipients, respectively.  
 
Table 1. Characteristics and prevalence of PTA among renal 
transplant recipients attending the Kidney Center of AMGH, Sana’a 
city (2014)* 
Characteristic n (%) 
Gender 
Male  72 (63.7) 
Female 41 (36.3) 
Age (years) 
<50  80 (70.8) 
≥50  33 (29.2) 
PTA type 
Early  7 (22.0) 
Late  19 (23.0) 
Donor type 
Living related donor  88 (77.9) 
Living unrelated donor  25 (22.1) 
History of acute rejection 
Yes  15 (13.3) 
No  98 (86.7) 
Immunosuppressive drugs used 
CsA with MMF and prednisone 67 (59.3) 
Tac with MMF and prednisone 46 (40.7) 
Treatment with ACEIs/ARBs  
 Yes 70 (62.0) 
No 43 (38.0) 
Pre-transplant EPO treatment 
Yes 39 (34.5) 
No 74 (65.5) 
Graft function 
Immediate  103 (91.2) 
Delayed 10 (8.8) 
* Total number of recruited renal transplant recipients is 113; CsA, 
cyclosporine A; MMF, mycophenolate mofetil; Tac, tacrolimus; ACEIs, 
angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor 
blockers; EPO, erythropoietin. 
 
Prevalence of PTA in the study was 23%. 
Seven (22.0%) of renal transplant recipients had 
early anemia (occured within 4–12 months post-
transplantation) while 19 (23.0%) of renal 
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recipients had late anemia (occured one year 
post-transplantation). 
3.2. Factors associated with PTA 
Bivariate analysis showed a significant 
association of PTA with age of 50 years or older 
(OR= 2.7; 95% CI: 1.10–6.72; P = 0.030), history 
of acute rejection (OR = 3.6; 95% CI: 1.17–11.28; 
P = 0.019) and delayed graft function (OR = 6.2; 
95% CI: 1.60–24.16; P = 0.004). However, no 
statistically significant association was observed 
between PTA and gender, treatment with CsA, 
Tac, or ACEIs/ARBs, graft source, pre-
transplantation treatement with EPO (Table 2). 
On the other hand, multivariable analysis 
identified history of acute rejection (adjusted OR 
= 3.9; 95% CI: 1.11–12.94; P = 0.034) and 
delayed graft function (adjusted OR = 4.6; 95% 
CI: 1.07–19.81; P = 0.040) as independent risk 
factors for PTA (Table 3).  
 
Table 2. Bivariable analysis of factors associated with PTA among Yemeni renal transplant recipients attending the Kidney Center of AMGH, 
Sana'a city (2014) 
Variable  N 
 
Anemia n(%) 
 
OR (95% CI) P value  
Gender   
Female 41 6 (14.6) Reference  
Male 72 20 (27.8) 2.2 (0.82–6.15) 0.110 
Age (years)   
<50  80 14 (17.5) Reference  
≥50  33 12 (36.4) 2.7 (1.10–6.72) 0.030* 
Donor type   
Living related donor  88 20 (22.7) Reference  
Living unrelated donor  25 6 (24.0) 1.1 (0.38–3.05) 0.890 
History of acute rejection   
No  98 19 (19.4) Reference  
Yes  15 7 (46.7) 3.6 (1.17–11.28) 0.019* 
Immunosuppressive drugs used   
CsA 66 17 (25.8) Reference  
Tac 47 9 (19.1) 0.68 (0.27–1.70) 0.410 
Treatment with ACEIs/ARBs    
Yes 70 18 (25.7) Reference  
No   43 8 (18.6) 0.72 (0.35–1.52) 0.380 
Pre-transplantation EPO treatment   
Yes 39 5 (12.8) Reference  
No 74 21 (28.4) 2.7 (0.93–7.83) 0.060 
Graft function   
Immediate 103 20 (19.4) Reference  
Delayed 10 6 (60.0) 6.2 (1.60–24.16) 0.004* 
N, Number of renal transplant recipients; n, anemic patients; OR, Odds ratio; CI, confidence interval; CsA, cyclosporine A; Tac, tacrolimus; ACEIs, angiotensin-
converting enzyme inhibitors; ARBs, angiotensin-receptor blockers; * statistically significant at P value <0.05. 
Table 3. Multivariable analysis of factors associated with PTA 
among Yemeni renal transplant recipients attending Kidney Center 
of AMGH, Sana'a city(2014) 
Variable  Adjusted OR (95% CI) P value  
History of acute rejection  3.9 (1.11–12.94) 0.034 
Delayed graft function  4.6 (1.07–19.81) 0.040 
OR, Odds ratio; CI, confidence interval. 
 
4. Discussion 
Anemia remains a common renaltransplant 
complication. The prevalence of PTA among 
Yemeni renal transplant recipients with 
functioning grafts was 23%. Early anemia 
represents 22.0%, while late anemia represents 
23.0%. Such a high PTA prevalence rate is in line 
with the published literature that PTA represents 
a common problem among renal transplant 
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recipients (6–11, 14, 15). However, the PTA 
prevalence rate concluded by the present study 
is lower than those reported by several previous 
studies elsewhere (6–11, 14, 15). This could be 
attributed to the inclusion criteria adopted in the 
present study, where only renal transplant 
recipients with functioning grafts were recruited. 
With this respect, Iwamoto et al. (21) reported a 
significant correlation between PTA and poor 
kidney graft function. 
The significant association of recipient’s age 
with PTA and the significantly higher proportion 
of PTA among renal recipients of 50 years or 
older than younger recipients are in agreement 
with previous studies (7, 21). The increase in 
PTA prevalence with age could be attributed to 
multiple factors such as iron and vitamin B12 
deficiencies, occult blood loss or chronic 
infections. However, several previous studies 
reported no statistically significant association 
between recipient’s age and PTA (4, 6, 12, 14, 
22). On the other hand, the significant 
association between the delayed graft function 
PTA among renal transplant recipients in the 
present study is in agreement with those 
reported from Egypt, where delayed graft 
function was found to be a risk factor for PTA 
(15, 23). Therefore, poor graft function could be 
a reason for developing PTA. In contrast, 
Banjeglav and Zibar (24) found no statistically 
significant association between delayed graft 
function and PTA among Croatian renal 
transplant recipients. 
The lack of association between PTA and the 
gender of Yemeni renal transplant recipients is 
consistent with the findings of previous studies 
elsewhere (4, 6, 22). In contrast, other studies 
reported that the female gender as a risk factor 
forthe development of PTA, which was explained 
by menstruation regain after the improvement of 
renal function (15, 24, 25). In another context, 
Yorgin et al. (26) showed that male American 
renal transplant recipients are more likely to 
have PTA than females (26). In the present study, 
the significant correlation between PTA and 
acute rejection episodes could be attributed to 
the kidney damage as a result of the 
inflammatory process. Similarly, acute rejection 
episodes were found to be associated with PTA 
among Egyptian renal transplant recipients (15, 
25). In contrast, a European multicenter study 
did not find acute rejection to be a risk factor for 
PTA, although patients who experienced more 
episodes of treated acute rejection had lower 
mean Hb levels (4). In contrast, Jalalzadeh et al. 
(27) reported that acute rejection episodes had 
no adverse effects on long-term renal graft 
function of Iranian renal transplant recipients 
after successful treatment. Moreover, some 
previous studies found no significant correlation 
between PTA and acute rejection (12, 14). On the 
other hand, the lack of association between PTA 
and EPO non-use prior to transplantation in the 
present study is contradictory to the findings of 
previous studies among Sudanese and Turkish 
renal transplant recipients (6, 14).  
In the Kidney Center of AMGH, the most 
frequently used calcineurin inhibitor is CsA 
followed by Tac, and all patients also receive 
MMF and prednisone. However, no significant 
association was found between PTA and the use 
of either drug. This finding is consistent with 
those reported by several previous studies (14, 
15, 22, 28). In contrast, this finding is in 
disagreement with those reported from 
European countries, where PTA was found to be 
associated with immunosuppressive treatments 
(4, 9, 29). Kolonko et al. (9) attributed the 
association between PTA and 
immunosuppression with CsA to the greater 
doses of MMF compared to those prescribed with 
Tac-based immunosuppressive treatment. On the 
other hand, the common treatment with ACEIs or 
ARBs among about two-thirds of renal transplant 
recipients in the present study was not 
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significantly associated with PTA. This finding is 
compatible with the findings in several previous 
studies reporting the lack of association between 
PTA and treatment with ACEIs and ARBs (6, 12, 
14, 15, 19, 22, 28, 30). 
The present study reveals that the majority 
of renal transplants (77.9%) were donated by 
living related donors, with absence of cadaveric 
donors. This finding is in agreement with those 
reported from Sudan and Turkey (6, 14). This is, 
however, dissimilar to those reported from the 
developed countries, where deceased donors are 
the major donor type in renal transplantation 
(11, 12). Like Sudanese and Turkish reports (6, 
14), no association was found between PTA 
among Yemeni renal transplant recipients and 
the source of grafts. 
5. Conclusions  
PTA is a common complication after kidney 
transplantation among Yemeni recipients with 
functioning grafts. Age of 50 years or older, 
history of acute rejection and delayed graft 
function are risk factors for PTA among renal 
transplant recipients. Moreover, history of acute 
rejection and delayed graft function represent 
independent predictors of PTA among Yemeni 
patients undergoing renal transplantation. 
Therefore, it is recommendedthat physicians 
involved in renal transplantation consider the 
investigation and follow-up of transplant 
recipients for PTA andadopt appropriate 
preventive and therapeutic measures. 
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